Wayne Kuznar

An orally administered first-in-class cancer stemness inhibitor, BBI608, administered twice daily with weekly paclitaxel has promising activity in patients with refractory, heavily pretreated metastatic pancreatic cancer; particularly in patients who are taxane naive.

Carboplatin/paclitaxel-based chemoradiotherapy (CarPacRT) has sufficient activity to progress into phase II clinical trials as neoadjuvant treatment for patients with resectable esophageal cancer.

Patients with renal cell carcinoma (RCC) who express higher entropy, a measure of T-cell diversity, could translate to a more favorable prognosis

Combining a selective class I oral histone deactylase (HDAC) inhibitor with high-dose interleukin (IL)-2 may boost the latter's antitumor effect in renal cell carcinoma (RCC).

The investigational anti-PD-L1 antibody avelumab showed antitumor activity within acceptable safety profile parameters in a recent phase Ib trial for metastatic urothelial cancer refractory to standard therapy.

A post hoc analysis of the phase III COU-AA-302 clinical trial suggests docetaxel can produce antitumor activity as the first subsequent therapy following disease progression with abiraterone acetate in men with chemotherapy-naive, metastatic castration-resistant prostate cancer.

Risk complications from mastectomy plus reconstruction was doubled when compared to lumpectomy plus whole breast irradiation after adjustment for other treatment differences.

Carboplatin combined with neoadjuvant chemotherapy improves disease-free survival significantly in women with triple-negative breast cancer but not HER2-positive breast cancer.

An assay that measures circulating tumor (ct) DNA in the urine can detect the early acquisition of epidermal growth factor receptor (EGFR) resistance mutations in patients with metastatic lung adenocarcinoma.

The 1.8-mg/kg dose of polatuzumab vedotin is as effective as the 2.4-mg/kg dose on the endpoint of progression-free survival in patients with relapsed/refractory non-Hodgkin lymphoma while improving tolerability, according to a pooled analysis of phase I and phase II clinical studies.

Low-frequency KRAS mutations are present in urine cell-free DNA in about 80% of patients with advanced cancers and BRAF V600E mutations.

Low-dose bevacizumab combined with lomustine has no significant effect on progression-free survival (PFS) or overall survival (OS) compared with standard-dose bevacizumab alone in patients with recurrent glioblastoma, according to results from a randomized phase II study.

Lenvatinib alone and in combination with everolimus significantly improved progression-free survival compared with everolimus alone in a phase II study of patients with metastatic renal cell carcinoma.

The addition of everolimus to sorafenib extended progression-free survival (PFS) in patients with metastatic differentiated thyroid carcinoma (DTC) that had progressed on sorafenib alone, according to findings from a single-arm open-label phase II study.

An immune checkpoint inhibitor combined with active immunotherapy has a potential positive effect on overall survival (OS) in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

The antiangiogenic agent pazopanib combined with paclitaxel showed significant antitumor activity in a phase II study of patients with relapsed/refractory urothelial cancer.

MPDL3280A, an investigational antibody that targets programmed death-ligand 1 (PD-L1), in combination with bevacizumab had strong antitumor activity and induced responses in 4 of 10 patients with mRCC.

Idelalisib monotherapy shows activity in treatment-naïve patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) — nearly 90% of patients enrolled in a phase II study demonstrated a partial response.

Selection of first-line treatments and the rational sequencing of therapies are the focus of current research in the treatment of pancreatic neuroendocrine tumors (NETs).

The combination of letrozole with either the CDK4/6 inhibitor LEE011 or the PI3 kinase Inhibitor BYL719 demonstrated clinical activity for women with ER-positive, HER2-negative breast cancer.

The poly (ADP-ribose) polymerase (PARP) inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA-wild type tumors.

A novel HER2-derived peptide (GP2) vaccine designed to stimulate CD8+ cytotoxic T-lymphocytes reduced the rate of breast cancer recurrence and proved safe and well tolerated in an adjuvant setting.

Long-term follow-up of a phase III clinical trial shows strong trends toward a greater likelihood of resuming menses and becoming pregnant when a luteinizing hormone-releasing hormone (LH-RH) analog is administered with chemotherapy in patients with breast cancer.

Breast conserving therapy (BCT) improves overall survival compared with other local treatments in patients with stage I breast cancer, according to an examination of the National Cancer Database (NCDB).

A better understanding of the molecular pathways that confer resistance to RAI in the treatment of differentiated thyroid cancer has led to success in targeting the VEGF and the VEGF receptor pathways.

Eighty-five percent of patients with EGFR-positive non-small cell lung cancer (NSCLC) experienced significant reduction in tumor growth rate with the addition of cabozantinib to erlotinib.

Continuing EGFR inhibition beyond progression with afatinib (Gilotrif) plus paclitaxel significantly improved PFS and ORR compared with chemotherapy alone in patients with heavily pretreated metastatic NSCLC.

The anti-PD-1 humanized antibody pembrolizumab (MK-3475) has robust antitumor activity as a first-line treatment for patients with advanced PD-L1-positive non–small cell lung cancer (NSCLC).

Adding necitumumab to standard of care with gemcitabine-cisplatin improves survival compared with chemotherapy alone as first-line treatment in patients with stage IV non–small cell lung cancer (NSCLC) of squamous histology.

Most medical oncologists in the United States would opt for an mTOR (mammalian target of rapamycin) inhibitor as second-line therapy for patients with metastatic clear cell renal cell carcinoma (mccRCC).